218779-77-2

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 218779-76-1 ethyl 4-(2-(tert-butoxy)-2-oxoethyl)cyclohexanecarboxylate 
• 279240-92-5 2-(4-(ethoxycarbonyl)cyclohexylidene)acetic acid 
• 218779-74-9 ethyl 4-(2-(tert-butoxy)-2-oxoethylidene)cyclohexanecarboxylate 

Downstream Products

• 403828-63-7 4-(4-oxo-3,4-dihydro-quinazolin-2-ylmethyl)-cyclohexanecarboxylic acid ethyl ester 
• 337971-89-8 4-(1H-Benzoimidazol-2-ylmethyl)-cyclohexanecarboxylic Acid Ethyl Ester 
• 1091599-81-3 ethyl 4-(2-hydroxyethyl)cyclohexanecarboxylate 
• 1260106-30-6 ethyl 4-(2-(1H-imidazol-1-yl)-2-oxoethyl)cyclohexanecarboxylate 
• 1260105-93-8 ethyl 4-(4-ethoxy-2,4-dioxobutyl)cyclohexanecarboxylate 
• 1260106-31-7 ethyl 4-((7-hydroxypyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260105-94-9 ethyl 4-((7-chloropyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260106-32-8 ethyl 4-((7-aminopyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260105-95-0 ethyl 4-((7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260105-96-1 ethyl 4-((7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260105-97-2 ethyl 4-((7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-chloropyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260105-98-3 ethyl 4-((7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260105-99-4 ethyl 4-((7-(bis((2-(trimethylsilyl)ethoxy)methyl)amino)-6-brorno-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 
• 1260106-33-9 ethyl 4-((6-acetyl-7-amino-3-(6-phenylpyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)methyl)cyclohexanecarboxylate 

Relevant academic research and scientific papers

ATX MODULATING AGENTS

Compounds of formula (I) can modulate the activity of autotaxin (ATX).

FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.

NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

2-Cyclohexyl quinazoline NMDA/NR2B antagonists

4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, amin

2-cyclohexyl quinazoline NMDA/NR2B antagonists

4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, amin

2-CYCLOHEXYL IMIDAZOPYRIDINE NMDA/NR2B ANTAGONISTS

4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C 1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C 6alkyl or aminocarbonyl chain a

2-cyclohexyl imidazopyridine NMDA/NR2B antagonists

4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino,

2-cyclohexyl benzimidazole NMDA/NR2B antagonists

Novel 4-substituted cyclohexanes substituted in the 1-position with 2-benzimidazoles, 2-imidazopyridines, or 4-imidazoles either directly or through a C1-C4alkyl, cycloalkyl, hydroxyalkyl, alkoxy or aminoalkyl chain are effective as